Clinical Research Directory
Browse clinical research sites, groups, and studies.
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
Sponsor: Nanostics
Summary
This ambispective observational cohort study will evaluate the clinical performance of the ClarityDX Prostate blood test in men with a prostate-specific antigen (PSA) level of 3 ng/mL or higher who are undergoing prostate biopsy due to suspicion of prostate cancer. The study will compare ClarityDX Prostate test results with biopsy outcomes to determine the test's ability to identify the presence of clinically significant prostate cancer.
Official title: Clinical Validation of ClarityDX Prostate as a Reflex Test to Prostate Specific Antigen (PSA) to Refine the Prediction of Clinically-significant Prostate Cancer
Key Details
Gender
MALE
Age Range
40 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
2800
Start Date
2019-06-06
Completion Date
2027-06
Last Updated
2026-07-24
Healthy Volunteers
No
Locations (3)
Johns Hopkins University
Baltimore, Maryland, United States
Prostate Cancer Centre
Calgary, Alberta, Canada
Kipnes Urology Centre
Edmonton, Alberta, Canada